BiQ: Adding Chimerix to Active Coverage (CMRX)

Chimerix (CMRX) has been added to Active Coverage. This was first communicated to Premium members this morning via BiQ Community Chat (click here for instructions on accessing the BiQ Community Chat Server.)

I first entered CMRX at a price of $.98 after the publication of P2 data for Dordaviprone, at which time CMRX was added to the BiQ Watch List pending further derisking. Now that the FDA has accepted the NDA with Priority Review, I feel there is sufficient derisking to add CMRX to the Active Portfolio.

While there is significant upside for shares over the long-term, I also see the potential for a pullback in the near term since there are no meaningful catalysts between now and the PDUFA target date for Dordaviprone. Members interested in the story may want to enter a position gradually on pullbacks--and pay close attention to position size in light of the FDA risk. While I think Dordaviprone has a better-than-average chance of approval, the FDA risk should not be ignored.

Biotech iQ is 100% subscriber supported. If you find this information helpful, please spread the word. You can also follow me on X @ Biotech iQ (_Biotech_iQ).

Biotech iQ is not an investment professional, and nothing on this page or this website should be considered investment advice. Please consult with a licensed investment professional as necessary. Past performance is not indicative of future results.